MA32968B1 - Composes quinazoline substitues - Google Patents

Composes quinazoline substitues

Info

Publication number
MA32968B1
MA32968B1 MA34018A MA34018A MA32968B1 MA 32968 B1 MA32968 B1 MA 32968B1 MA 34018 A MA34018 A MA 34018A MA 34018 A MA34018 A MA 34018A MA 32968 B1 MA32968 B1 MA 32968B1
Authority
MA
Morocco
Prior art keywords
methods
kinase
disorder
substituted quinazoline
compounds
Prior art date
Application number
MA34018A
Other languages
Arabic (ar)
English (en)
Inventor
Caroline Leriche
Eric Auclair
Roux Jacques Le
David N Middlemiss
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41735344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32968(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of MA32968B1 publication Critical patent/MA32968B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION PORTE SUR CERTAINS COMPOSÉS NOUVEAUX, SUR LEURS MÉTHODES DE PRODUCTION ET SUR DES MÉTHODES DE TRAITEMENT OU D'AMÉLIORATION D'UN TROUBLE À MÉDIATION PAR UNE KINASE. PLUS PARTICULIÈREMENT, CETTE INVENTION PORTE SUR DES COMPOSÉS QUINAZOLINE SUBSTITUÉS UTILES EN TANT QU'INHIBITEURS DE KINASE SÉLECTIFS, SUR DES MÉTHODES DE PRODUCTION DE TELS COMPOSÉS ET SUR DES MÉTHODES DE TRAITEMENT OU D'AMÉLIORATION D'UN TROUBLE ENTRAÎNÉ PAR UNE KINASE. EN PARTICULIER, LES MÉTHODES PORTENT SUR LE TRAITEMENT OU L'AMÉLIORATION D'UN TROUBLE ENTRAÎNÉ PAR UNE KINASE COMPRENANT LES MALADIES CARDIO-VASCULAIRES, LE DIABÈTE, LES TROUBLES LIÉS AU DIABÈTE, LES MALADIES INFLAMMATOIRES, LES TROUBLES IMMUNOLOGIQUES, LE CANCER ET LES MALADIES DES YEUX TELLES QUE LES RÉTINOPATHIES OU LA DÉGÉNÉRESCENCE MACULAIRE OU AUTRE MALADIE VITRÉO-RÉTINIENNE ET SIMILAIRE.
MA34018A 2008-12-29 2009-12-18 Composes quinazoline substitues MA32968B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08360043 2008-12-29
PCT/EP2009/067494 WO2010076238A1 (fr) 2008-12-29 2009-12-18 Composés quinazoline substitués

Publications (1)

Publication Number Publication Date
MA32968B1 true MA32968B1 (fr) 2012-01-02

Family

ID=41735344

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34018A MA32968B1 (fr) 2008-12-29 2009-12-18 Composes quinazoline substitues

Country Status (23)

Country Link
US (1) US8389530B2 (fr)
EP (1) EP2381943A1 (fr)
JP (1) JP2012514020A (fr)
KR (1) KR20110120878A (fr)
CN (1) CN102333533A (fr)
AU (1) AU2009334869A1 (fr)
BR (1) BRPI0924067A2 (fr)
CA (1) CA2748319A1 (fr)
CO (1) CO6390105A2 (fr)
CR (1) CR20110368A (fr)
DO (1) DOP2011000209A (fr)
EA (1) EA019110B1 (fr)
EC (1) ECSP11011204A (fr)
IL (1) IL213742A0 (fr)
MA (1) MA32968B1 (fr)
MX (1) MX2011007064A (fr)
NI (1) NI201100134A (fr)
NZ (1) NZ593949A (fr)
PE (1) PE20120424A1 (fr)
SG (1) SG172415A1 (fr)
TN (1) TN2011000319A1 (fr)
WO (1) WO2010076238A1 (fr)
ZA (1) ZA201104777B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201204723A (en) 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
WO2015108992A1 (fr) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Composés hétérobicycliques et leur utilisation en tant qu'inhibiteurs du récepteur fgfr4
KR101715448B1 (ko) * 2014-07-16 2017-03-20 주식회사 큐리언트 염증성 질환 치료용 화합물
CA2972014C (fr) 2014-12-24 2019-09-24 Gilead Sciences, Inc. Composes de pyrimidine fusionnes pour le traitement du vih
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
SG11201705184PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Isoquinoline compounds for the treatment of hiv
CN112239459B (zh) * 2019-07-19 2021-11-26 中国科学院上海药物研究所 稠环嘧啶氨基化合物、其制备方法、药物组合物及应用
CN115916759B (zh) * 2020-06-19 2025-07-15 泰州红云制药有限公司 取代喹唑啉类化合物、其制备方法、药物组合及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2386955A1 (fr) * 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines et leur utilisation dans l'inhibition des enzymes kinase dependant de la cycline
EP1590341B1 (fr) 2003-01-17 2009-06-17 Warner-Lambert Company LLC Heterocycles 2-aminopyridines substitues utilises comme inhibiteurs de la proliferation cellulaire
WO2005037285A1 (fr) 2003-10-16 2005-04-28 Chiron Corporation Quinoxalines, quinolines, isoquinolines et quinazolines 2,6-bisubstituees servant d'inhibiteurs a la kinase raf pour le traitement du cancer
AU2005231507B2 (en) 2004-04-08 2012-03-01 Targegen, Inc. Benzotriazine inhibitors of kinases
NZ588896A (en) 2004-08-25 2012-05-25 Targegen Inc Heterocyclic compounds and methods of use
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
WO2006101977A2 (fr) 2005-03-16 2006-09-28 Targegen, Inc. Composes de pyrimidine et methodes d'utilisation
EP1878727A4 (fr) * 2005-04-28 2013-11-13 Kyowa Hakko Kirin Co Ltd Dérivés de 2-aminoquinazoline
WO2006133411A1 (fr) 2005-06-08 2006-12-14 Targegen, Inc. Methodes et preparations pour le traitement de troubles oculaires
TW200808739A (en) * 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
CA2673003A1 (fr) * 2006-12-22 2008-07-03 Novartis Ag Quinazolines destines a l'inhibition de pdk1

Also Published As

Publication number Publication date
EA201101012A1 (ru) 2012-01-30
NZ593949A (en) 2013-08-30
TN2011000319A1 (en) 2012-12-17
SG172415A1 (en) 2011-07-28
US8389530B2 (en) 2013-03-05
CO6390105A2 (es) 2012-02-29
CN102333533A (zh) 2012-01-25
ECSP11011204A (es) 2011-10-31
CR20110368A (es) 2011-12-02
BRPI0924067A2 (pt) 2016-01-26
ZA201104777B (en) 2012-03-28
MX2011007064A (es) 2012-01-20
IL213742A0 (en) 2011-07-31
NI201100134A (es) 2012-03-06
AU2009334869A1 (en) 2011-07-14
DOP2011000209A (es) 2011-09-30
PE20120424A1 (es) 2012-05-04
WO2010076238A1 (fr) 2010-07-08
KR20110120878A (ko) 2011-11-04
AU2009334869A2 (en) 2011-09-29
US20120004210A1 (en) 2012-01-05
EA019110B1 (ru) 2014-01-30
EP2381943A1 (fr) 2011-11-02
CA2748319A1 (fr) 2010-07-08
JP2012514020A (ja) 2012-06-21

Similar Documents

Publication Publication Date Title
CY1122238T1 (el) Νεα 1-ναφθυλ-3-αζαδικυκλο[3.1.0]εξανia: παρασκευη και χρηση για τη θεραπεια νευροψυχιατρικων διαταραχων
MA32975B1 (fr) Antagonistes de c5ar
UA116614C2 (uk) Антитіло до фактора d і його застосування
MA31999B1 (fr) Proteines de liaison a l'antigene
MX2007005870A (es) Composiciones que comprenden derivados de escilo-inositol y metodos para tratar trastornos de agregacion de proteinas.
MA30337B1 (fr) Anticorps
MX2024015884A (es) Anticuerpos anti-ror1 y conjugados de anticuerpos anti-ror1, composiciones que comprenden anticuerpos anti-ror1 o conjugados de anticuerpos anti-ror1, y metodos para hacer y usar anticuerpos anti-ror1 y conjugados de anticuerpos anti-ror1
ATE548363T1 (de) 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen
MA33604B1 (fr) Composés et compositions en tant qu'inhibiteurs de protéine kinase
MA30876B1 (fr) Anticorps de la lymphotoxine-alpha
NO20091759L (no) Forbindelser og sammensetninger som protein kinase inhibitorer
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA30557B1 (fr) Composés de pyrrolopyrimidine et leurs utilisations.
MA45811A (fr) Méthodes et compositions de traitement de maladie.
CY1117317T1 (el) Αναστολεις κινασης janus για θεραπεια ξηροφθαλμιας και αλλων σχετικων με τον οφθαλμο ασθενειων
TW200630356A (en) Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole
TN2012000073A1 (fr) Derives des l-(piperidine-4-yl) pyrazole servant de modulateurs de gpr119
MA33716B1 (fr) Mutants de fgf21 et leurs utilisations
MA33534B1 (fr) Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine
MX2010003325A (es) Anticuepos novedosos.
TN2009000323A1 (en) Modulators of sclerostin binding partners for treating bone-related disorders
MA33926B1 (fr) Aminopyrimidines en tant qu'inhibiteurs de la syk
MA38076A1 (fr) Dérivés d'oxazolidin-2-one-pyrimidine
MA47392B1 (fr) Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
MX2012004548A (es) Nuevas composiciones para prevenir y/o tratar transtornos degenerativos del sistema nervioso central.